HLA class I antigen display on hepatocyte membrane in chronic hepatitis B virus infection: Its role in the pathogenesis of chronic type B hepatitis
Chia‐Ming Chu, Wei‐Chue Shyu, Ruey‐Wen Kuo, Yun‐Fan Liaw – 1 May 1988 – It has been suggested that cytotoxic T cells are involved in the recognition and lysis of the infected hepatocytes in chronic hepatitis B virus infection, and that the target antigen is probably HBcAg which is displayed on the hepatocyte membrane during active viral replication. However, studies in other viral infection have demonstrated that cytotoxic T cells recognize viral antigen on the infected cells only in the context of HLA class I antigens.
Identification of biliprotein as a liver growth factor
Juan J. Díaz‐Gil, Gonzalo Sánchez, Carolina Trilla, Pedro Escartín – 1 May 1988 – We determined the concentration of biliprotein in plasma of rats at different times after partial hepatectomy. From the same plasma samples, we purified a liver growth factor previously characterized by our group. When we plotted the 14 points studied, a linear relationship was obtained (r = 0.999; p < 0.001). This result, in addition to our group's recent identification of this liver growth factor as an albumin‐bilirubin complex, strongly suggests that biliprotein is a liver growth factor.
Systemic and splanchnic hemodynamic effects of intravenous hypertonic glucose in patients with cirrhosis
Domenico Pugliese, Samuel S. Lee, Abraham Koshy, Raimondo Cerini, Yves Ozier, Didier Lebrec – 1 May 1988 – In animals, there may exist a hyperemic response in the portal circulation during intravenous administration of hypertonic glucose, but a hemodynamic response of this kind has never been described in man. This study was designed to evaluate if hyperglycemia itself could induce systemic or splanchnic hemodynamic changes in patients with cirrhosis. Sixteen patients with cirrhosis were studied before and during i.v.
Masthead
1 May 1988
Pilot study of recombinant human interleukin 2 for chronic type B hepatitis
Shinichi Kakumu, Akihiko Fuji, Kentaro Yoshioka, Hirofumi Tahara, Yoshiyuki Ohtani, Hideo Hirofuji, Kenichi Murase, Tsuneto Aoi – 1 May 1988 – Recombinant human interleukin 2 was administered to 10 patients with chronic type B hepatitis as a part of a pilot study to evaluate its antiviral activity. Patients received 1 to 3 x 105 units per day of interleukin 2 for 21 to 28 days, and all completed the treatment schedule. During therapy, serum values of DNA polymerase decreased in 6 and became negative in four patients.
Experimental duck hepatitis B virus infection: Pathology and evolution of hepatic and extrahepatic infection
John S. Freiman, Allison R. Jilbert, Robert J. Dixon, Marlis Holmes, Eric J. Gowans, Christopher J. Burrell, Edward J. Wills, Yvonne E. Cossart – 1 May 1988 – Seventy, 1‐day‐old ducklings inoculated intraperitoneally with duck hepatitis B virus and 30 controls have been studied over a 2‐year period. Infection with duck hepatitis B virus occurred in all inoculated ducks, although this was not associated with clinical morbidity.
Postprandial hemodynamic responses in patients with cirrhosis
Samuel S. Lee, Antoine Hadengue, Richard Moreau, Raymond Sayegh, Patrick Hillon, Didier Lebrec – 1 May 1988 – The hemodynamic response to a 800 kcal liquid meal was investigated in 24 patients (study group) with cirrhosis and two control groups. One control group of six cirrhotic patients (volume control) had a calorie‐free equivolumic electrolyte solution. The second control group (normal control) of six patients with normal hepatic function had the same test meal.